Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 600 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Insulin - Placebo Clear all
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp

NCT05456854
View directory record Official record
Conditions
Metabolic Disease
Interventions
Hyperglycemic Clamp, Kisspeptin-10, Placebo
Diagnostic Test · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Sep 6, 2026, 10:13 AM EDT
Withdrawn Phase 2 Interventional

Insulin Resistance and Androgen Deprivation Therapy

NCT04995978
View directory record Official record
Conditions
Prostate Cancer, Insulin Resistance
Interventions
Pioglitazone 30 mg, placebo tablet
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 85 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 6, 2026, 10:13 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome

NCT01753674
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Resistance
Interventions
TA-65, Placebo
Dietary Supplement
Lead sponsor
University of Connecticut
Other
Eligibility
35 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 6, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

NCT01011868
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773 placebo, BI 10773 low dose, BI 10773 high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Sep 6, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy Study of Intranasal Insulin to Treat Tobacco Abstinence Syndrome

NCT01781234
View directory record Official record
Conditions
Tobacco Abstinence Syndrome
Interventions
Intranasal Insulin, Placebo
Drug
Lead sponsor
Ajna Hamidovic
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 9, 2018 · Synced Sep 6, 2026, 10:13 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Resveratrol in Type2 Diabetes and Obesity

NCT01158417
View directory record Official record
Conditions
Type 2 Diabetes, Obesity, Insulin Resistance
Interventions
Placebo, Resveratrol 40 mg oral three times a day, Resveratrol 500 mg oral once daily.
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
20 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Sep 6, 2026, 10:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans

NCT01375491
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Doxycycline, Placebo
Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 6, 2026, 10:13 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II)

NCT02959762
View directory record Official record
Conditions
Obesity, Insulin Resistance, Obesity in Diabetes, Nutritional and Metabolic Diseases, Hyperlipidemia, Hyperglycemia, Cardiovascular Diseases
Interventions
Placebo-Control, Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d), High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
8 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Sep 6, 2026, 10:13 AM EDT
Not yet recruiting Phase 2 Interventional

Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease

NCT07756294
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Empagliflozin, Insulin, Insulin Placebo, Empagliflozin Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 6, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality

NCT00782795
View directory record Official record
Conditions
Chronic Pancreatitis, Insulin Resistance, Normal or Mildly Abnormal Stool Fat Levels
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Sep 6, 2026, 10:13 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Supplements for Controlling Resistance to Insulin

NCT00699413
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2
Interventions
nutrition education plus active supplement, nutrition education plus inactive supplement
Drug
Lead sponsor
University of Southern California
Other
Eligibility
13 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 6, 2026, 10:13 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase

NCT04028960
View directory record Official record
Conditions
Type1diabetes
Interventions
Regular insulin (Humulin-R), intranasal route, SipNose intranasal device
Drug · Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Sep 6, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus

NCT00419562
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Oral Insulin, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years to 45 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
13
States / cities
San Francisco, California • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Sep 6, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Alogliptin Pediatric Study

NCT02856113
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Alogliptin Benzoate, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
10 Years to 17 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
34
States / cities
Little Rock, Arkansas • Los Angeles, California • Palmdale, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Sep 6, 2026, 10:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Endogenous Opioid Activity and Affective State in Insulin Resistant Women

NCT02069379
View directory record Official record
Conditions
Depression, Insulin Resistance, Metabolic Syndrome
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Sep 6, 2026, 10:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Metformin to Augment Low Milk Supply (MALMS) Study

NCT02179788
View directory record Official record
Conditions
Low Milk Supply, Pre-diabetes, Insulin Resistance, Suppressed Lactation
Interventions
Standard care, Metformin, Placebo
Behavioral · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
20 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 6, 2026, 10:13 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Exogenous Ketones on Cognitive Function in Older Adults With Prediabetes?

NCT07546409
View directory record Official record
Conditions
Prediabetes, Healthy (Controls)
Interventions
Ketone Monoester (KE), Placebo
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 6, 2026, 10:13 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes

NCT06931275
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
EMR-based BPA model, Placebo (EMR-based without BPA model)
Other · Behavioral
Lead sponsor
T1D Exchange, United States
Other
Eligibility
2 Years to 95 Years
Enrollment
1,178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Sep 6, 2026, 10:13 AM EDT
Active, not recruiting Phase 2 Interventional

Effects of GRA in Patients With Type 1

NCT04779645
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
REMD-477, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 6, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

NCT01617434
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
31
States / cities
Phoenix, Arizona • Anaheim, California • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 6, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency

NCT01007071
View directory record Official record
Conditions
Hypopituitarism
Interventions
Human Growth Hormone (1-134), Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 6, 2026, 10:13 AM EDT
Terminated Phase 1 Interventional

Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome

NCT00438321
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Zoladex, Testosterone gel, Anastrozole Pill, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years to 75 Years · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 6, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of BVS857 in Subjects With Insulin Resistance

NCT01435330
View directory record Official record
Conditions
Insulin Resistance
Interventions
BVS857, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 64 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Chula Vista, California • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 6, 2026, 10:13 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Novel Fiber on Glucose Homeostasis in Individuals at Risk for Diabetes

NCT00820807
View directory record Official record
Conditions
Insulin Resistance
Interventions
Novel dietary fiber, Placebo
Other
Lead sponsor
Cargill
Industry
Eligibility
30 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Sep 6, 2026, 10:13 AM EDT